The Hetero Ring Is Four-membered Patents (Class 549/510)
-
Patent number: 11857953Abstract: A method of making a boronated zeolite catalyst includes preparing an initial slurry comprising water, a shape selective zeolite, boric acid, and a weak acid selected from the group consisting of oxalic acid, citric acid, and oxalic acid and citric acid, hydrothermally treating the initial slurry at a temperature of from 70° C. to 90° C. to produce a hydrothermally treated slurry comprising dealuminated zeolite particles, adjusting the pH of the hydrothermally treated slurry to an intermediate pH of from 8 to 9 to produce a basic slurry, after adjusting the pH to the intermediate pH, hydrothermally treating the basic slurry at a temperature of from 70° C. to 90° C. to produce a boronated zeolite slurry, removing liquids from the boronated zeolite slurry to produce a boronated zeolite filtrate, and drying and calcining the boronated zeolite filtrate to produce the boronated zeolite catalyst.Type: GrantFiled: October 31, 2022Date of Patent: January 2, 2024Assignee: Saudi Arabian Oil CompanyInventors: Hashim N. Al Khunaizi, Ahmad A. Jazzar, Shatha A. Alabbad, Donya A. Sewdan, Qasim Saleem
-
Patent number: 11590232Abstract: A bioconjugate comprising at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure.Type: GrantFiled: July 18, 2019Date of Patent: February 28, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAYInventors: Patrick Couvreur, Jiao Feng, Sinda Lepetre-Mouelhi
-
Patent number: 11555022Abstract: A group of polyfunctional oxetane-based compounds having a structure as represented by general formula (I) or a product obtained by a reaction between a compound of general formula (I) and epichlorohydrin, an ester compound, or an isocyanate compound. When these polyfunctional oxetane-based compounds are used as cation polymerizable monomers in combination with an epoxy compound, the curing speed is high, and the cured product has highly excellent hardness, flexibility, adherence, and heat resistance.Type: GrantFiled: November 5, 2020Date of Patent: January 17, 2023Assignees: CHANGZHOU TRONLY NEW ELECTRONIC MATERIALS CO., LTD., CHANGZHOU TRONLY ADVANCED ELECTRONIC MATERIALS CO., LTD.Inventor: Xiaochun Qian
-
Patent number: 11171309Abstract: The present application relates to an encapsulating composition and an organic electronic device comprising the same, and provides an encapsulating composition which can effectively block moisture or oxygen introduced into an organic electronic device from the outside to secure the lifetime of the organic electronic device, is possible to realize a top emission type organic electronic device, is applicable to an inkjet method and can provide a thin display.Type: GrantFiled: December 11, 2017Date of Patent: November 9, 2021Assignee: LG Chem, Ltd.Inventors: Yu Jin Woo, Joon Hyung Kim, Kook Hyun Choi, Mi Lim Yu
-
Patent number: 11129902Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.Type: GrantFiled: August 12, 2020Date of Patent: September 28, 2021Inventor: Mamoun M Alhamadsheh
-
Patent number: 10906882Abstract: A group of polyfunctional oxetane-based compounds having a structure as represented by general formula (I) or a product obtained by a reaction between a compound of general formula (I) and epichlorohydrin, an ester compound, or an isocyanate compound. When these polyfunctional oxetane-based compounds are used as cation polymerizable monomers in combination with an epoxy compound, the curing speed is high, and the cured product has highly excellent hardness, flexibility, adherence, and heat resistance.Type: GrantFiled: January 11, 2019Date of Patent: February 2, 2021Assignee: CHANGZHOU TRONLY ADVANCED ELECTRONIC MATERIALS CO., LTD.Inventor: Xiaochun Qian
-
Patent number: 10555926Abstract: The present invention relates to cabazitaxel for use in a method for treating an AR-V7-positive patient suffering from prostate cancer comprising determining the AR-V7-status in said patient and administering cabazitaxel. The invention also relates to a method of identifying patients with prostate cancer, eligible for treatment with cabazitaxel comprising testing a biological sample from the patient for the presence of AR-V7 circulating tumor cells, wherein the patient is eligible for treatment with said cabazitaxel if circulating tumor cells in said sample test positive for AR-V7. The invention further relates to a kit of parts for determining the AR-V7-status in isolated tumor cells of a patient with prostate cancer.Type: GrantFiled: February 17, 2016Date of Patent: February 11, 2020Assignee: Erasmus University Medical Center RotterdamInventors: Stefan Sleijfer, Wendy Onstenk, Anita Maria Sieuwerts
-
Patent number: 10500278Abstract: A method of treating a subject who has been diagnosed with cancer is described. The method includes characterizing the radiation-susceptibility of the subject by detecting a mutation in an NRF2 pathway protein in suitable sample obtained from the subject and treating the subject with radiation therapy if the subject is characterized as being radiation-susceptible, or treating the subject with radiation therapy and a radiosensitizing agent if the subject is characterized as being radioresistant. A method of determining if a subject has a history of tobacco smoking is also described that includes analyzing an NRF2 pathway protein to determine if a mutation is present in suitable sample obtained from the subject and characterizing the subject as having a history of tobacco smoking if a genetic fingerprint consistent with tobacco exposure is identified.Type: GrantFiled: August 21, 2015Date of Patent: December 10, 2019Assignee: THE CLEVELAND CLINIC FOUNDATIONInventor: Mohamed Abazeed
-
Patent number: 10314809Abstract: Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.Type: GrantFiled: July 8, 2015Date of Patent: June 11, 2019Assignee: SHANDONG XINCHUANG BIOTECHNOLOGY CO., LTD.Inventors: Laitian Xing, Yong Wang, Mingqian Wei, Yanqiu Xing, Lianlian Li, Lichao Xing, Guangxia Deng, Hong Meng, Tao Huang, Dongxia Yang
-
Patent number: 10149911Abstract: This pharmaceutical composition contains a hydroxamic acid derivative, or a salt thereof, and a solubilizer, said hydroxamic acid derivative being selected from among (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, 2S)-2-((4-((4-((1R)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, and (2S)-N-hydroxy-2-((4-((4-((1S)-1-hydroxy-2-methoxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N?,2-dimethylmalonamide. The pharmaceutical composition demonstrates strong antibacterial activity, has excellent solubility in water, and is useful as a drug.Type: GrantFiled: September 11, 2015Date of Patent: December 11, 2018Assignee: TOYAMA CHEMICAL CO., LTD.Inventors: Tatsuya Honda, Yuko Suzumura, Tomoya Kato, Yu Koseki, Kohei Ono
-
Patent number: 9815806Abstract: The present invention provides an improved process for the preparation of 4?-acetoxy-2?-benzoyloxy-5?,20-epoxy-1?,13?-dihydroxy-7?,10?-dimethoxy-9-oxo-11-taxene (7?,10?-dimethoxy-10-deacetoxybaccatin III). The present invention also provides a novel process for the preparation of cabazitaxel.Type: GrantFiled: December 14, 2015Date of Patent: November 14, 2017Assignee: Hetero Research FoundationInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Adulla Venkat Narsimha Reddy, Bandi Vamsi Krishna
-
Patent number: 9802951Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: July 25, 2013Date of Patent: October 31, 2017Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Patent number: 9586919Abstract: The present invention relates to a new anhydrous crystalline form of Cabazitaxel of formula (I), designated as form H. A further object of the present invention is a processes for the preparation of the above mentioned form H by recrystallization of Cabazitaxel from a mixture of decanoyl- and octanoyl triglycerides or from glycerol trioctanoate. Form H of Cabazitaxel is useful for the preparation of Cabazitaxel, Cabazitaxel salts, and polymorphic forms thereof. It is also particularly useful as a medicament, especially for the treatment of cancers.Type: GrantFiled: October 9, 2014Date of Patent: March 7, 2017Assignee: INDENA S.P.A.Inventors: Walter Cabri, Daniele Ciceri, Luca Domenighini, Andrea Gambini, Federico Peterlongo
-
Patent number: 9487496Abstract: The present invention relates to a novel process for preparation of cabazitaxel (I) starting from 10-Deacetyl baccatin or derivative that involves methylation of 7, 10 —OH groups. Also provided is a novel process using chiral bis-lactam linker for the synthesis of cabazitaxel.Type: GrantFiled: October 31, 2013Date of Patent: November 8, 2016Assignee: Intas Pharmaceuticals LimitedInventors: Mettilda Lourdusamy, Ioan Iosif Radu, Rahul Chandrashayi Saxena, Raghvendra Jayantibhai Patel, Sandeep Bachubhai Shah
-
Patent number: 9434740Abstract: The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.Type: GrantFiled: July 8, 2014Date of Patent: September 6, 2016Assignee: ODONATE THERAPEUTICS, LLCInventors: John K. Thottathil, Raymond P. Warrell
-
Patent number: 9403785Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.Type: GrantFiled: December 26, 2012Date of Patent: August 2, 2016Assignee: SHILPA MEDICARE LIMITEDInventors: Vimal Kumar Shrawat, Prashant Purohit, Rafiuddin Dr, Vinod Kumar Singh, Akshay Kant Chaturvedi
-
Patent number: 9402824Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.Type: GrantFiled: January 23, 2015Date of Patent: August 2, 2016Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Patent number: 9394266Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.Type: GrantFiled: March 7, 2013Date of Patent: July 19, 2016Assignee: Ivax International GmBhInventors: Pavel Vraspir, Alexandr Jegorov, Roman Gabriel, Ales Gavenda
-
Patent number: 9284327Abstract: The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.Type: GrantFiled: March 6, 2014Date of Patent: March 15, 2016Assignee: GFV, LLCInventors: John K. Thottathil, Raymond P. Warrell
-
Patent number: 9133152Abstract: A process for the preparation of 10-deacetyl-7,10-bis-trichloroacetylbaccatine III with HPLC purity higher than 99% and free from 2-debenzoyl-2-pentenoylbaccatine III by purification of 10-deacetyl-7,10-bis-trichloroacetylbaccatineIII followed by alkaline hydrolysis of the protecting groups in position 7 and 10.Type: GrantFiled: April 7, 2006Date of Patent: September 15, 2015Assignee: INDENA S.P.A.Inventors: Bruno Gabetta, Andrea Gambini
-
Patent number: 9127208Abstract: The present invention is related to a thermal extract of a plant material and methods of extraction thereof. The method of producing a thermal extract from a plant starting material by means of a thermal extraction of the starting material wherein the improvement consists in requiring smaller amounts of costly and/or toxic organic solvents for the extraction and partitioning steps.Type: GrantFiled: April 2, 2007Date of Patent: September 8, 2015Assignee: Pharmatherm Chemicals, Inc.Inventors: David Boulard, Robert G. Graham, Barry Freel
-
Patent number: 9119877Abstract: The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.Type: GrantFiled: November 17, 2010Date of Patent: September 1, 2015Assignee: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Dario Ballinari, Antonella Ciavolella, Enrico Pesenti, Alessia Montagnoli
-
Patent number: 9078929Abstract: The present invention relates to ?-polylysine conjugates, in particular conjugates of ?-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney.Type: GrantFiled: July 9, 2010Date of Patent: July 14, 2015Assignee: Merck Patent GmbHInventors: Armin Kuebelbeck, Gregor Larbig, Walter Mier, Barbro Beijer, Uwe Haberkorn
-
Patent number: 9062018Abstract: A crystalline from of 13-[(N-tert-butoxycarbonyl)-2?-O-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III.Type: GrantFiled: October 27, 2011Date of Patent: June 23, 2015Assignee: Indena S.p.AInventors: Daniele Ciceri, Andrea Gambini, Maurizio Ricotti, Nicola Sardone
-
Publication number: 20150141674Abstract: The present invention relates to the field of medical chemistry, and discloses a preparing method for three crystal forms of cabazitaxel, that is, crystalline form J of cabazitaxel esterate, crystalline form G of cabazitaxel hydrate and crystalline form I of cabazitaxel, and a novel crystalline form of cabazitaxel. The novel crystalline form of cabazitaxel according to the invention has good stability and good solubility in commonly used solvents, and is easy to be preserved and is stable under treatment during preparation of dosage forms, thus could be used for the preparation of a medicament for treating prostate cancer.Type: ApplicationFiled: July 18, 2013Publication date: May 21, 2015Inventors: Jing Li, Quanxing Yao
-
Publication number: 20150141673Abstract: The present invention relates to a novel crystalline polymorph form W of cabazitaxel and to method for the preparation thereof.Type: ApplicationFiled: November 15, 2013Publication date: May 21, 2015Inventors: Honghai Song, Xingfeng Wang, Song Lin
-
Publication number: 20150125741Abstract: A secondary battery includes: a cathode; an anode; and non-aqueous electrolytic solution including a cyclic ether compound that includes a skeleton and one or more substituent groups introduced into the skeleton. The skeleton includes one or more four-or-more-membered oxygen-containing rings. The one or more substituent groups each are a monovalent group represented by Formula (1). —X—O—R??(1) (X is one of a divalent chain saturated hydrocarbon group, a halide group thereof, and nothing. R is one of a monovalent chain saturated hydrocarbon group, etc. At least one of one or more Rs includes one or more of the monovalent chain unsaturated hydrocarbon group, the monovalent cyclic unsaturated hydrocarbon group, the monovalent oxygen-containing cyclic unsaturated hydrocarbon group, the halide group thereof, and the monovalent group obtained by bonding two or more thereof, and includes a carbon-carbon multiple bond (one of —C?C— and —C?C—) bonded to an ether bond (—O—).Type: ApplicationFiled: October 24, 2014Publication date: May 7, 2015Inventors: Toru ODANI, Tadahiko KUBOTA
-
Publication number: 20150119589Abstract: This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions amenable for large-scale commercial production.Type: ApplicationFiled: May 1, 2013Publication date: April 30, 2015Inventors: Magnus Carl Arne Eriksson, Suresh R. Kapadia, Jonathan Timothy Reeves, Xingzhong Zeng
-
Publication number: 20150110805Abstract: Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention provides methods for treating conditions such as autoimmune diseases, degenerative diseases, and graft-versus-host disease. The present invention also relates to methods of determining when therapy should be administered to a patient.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Inventors: Martin Leonard Ashdown, Luisa Maria Ashdown
-
Patent number: 9012665Abstract: The present invention is directed to an amorphous form of cabazitaxel, which can be prepared by dissolving a solid form of cabazitaxel in an organic solvent, and removing the organic solvent to dryness. The amorphous form of cabazitaxel is characterized by DSC as in FIG. 1 and/or X-ray powder diffraction pattern as in FIG. 2.Type: GrantFiled: July 26, 2013Date of Patent: April 21, 2015Assignee: Yung Shin Pharm. Ind. Co., Ltd.Inventors: Liang-Rern Kung, Yi-Ting Hung, Tung-Shen Fang, Po-Wei Chang, Tsang-Miao Huang
-
Patent number: 9000193Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).Type: GrantFiled: November 5, 2014Date of Patent: April 7, 2015Assignee: Fresenius Kabi Oncology LimitedInventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
-
Patent number: 8993790Abstract: Provide is an oxetane-ring containing (meth) acrylic ester compound which can give, through polymerization, a cured article being highly flexible or thermally stable. The oxetane-ring-containing (meth) acrylic ester compound is represented by formula (1) below, in which R1 represents a hydrogen atom or an alkyl group; R2 represent a hydrogen atom or a methyl group; and “A” represent either a linear alkylene group represented by following formula (a1) or a branched-chain alkylene group represented by following formula (a2).Type: GrantFiled: November 5, 2010Date of Patent: March 31, 2015Assignee: Daicel CorporationInventors: Tamaki Son, Kiyoshi Ikura
-
Patent number: 8981040Abstract: Provided is a cationically polymerizable resin which is rapidly cured upon irradiation with light and forms a cured product excellent in flexibility and thermal stability. The cationically polymerizable resin is obtained through radical polymerization of an oxetane-ring-containing (meth)acryloyl compound represented by following Formula (1) alone or in combination with another radically polymerizable compound. In the formula, R1 represents hydrogen atom or methyl group; R2 represents hydrogen atom or an alkyl group; and “A” represents a linear or branched chain alkylene group having 2 to 20 carbon atoms.Type: GrantFiled: January 24, 2011Date of Patent: March 17, 2015Assignee: Daicel CorporationInventors: Naoko Araki, Yoshinori Funaki, Kiyoharu Tsutsumi, Tomoaki Mahiko
-
Publication number: 20150073159Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel.Type: ApplicationFiled: November 19, 2014Publication date: March 12, 2015Inventors: Ondrej SIMO, Pavel VRASPIR, Tomas HOLAS, Alexandr JEGOROV, Roman GABRIEL
-
Publication number: 20150072969Abstract: The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40 comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).Type: ApplicationFiled: February 27, 2013Publication date: March 12, 2015Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Sanjay Kumar, Rajiv Sharma, Vishal Ashok Mahajan, Sangameshwar Prabhakar Sawargave
-
Publication number: 20150072396Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.Type: ApplicationFiled: March 1, 2012Publication date: March 12, 2015Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
-
Publication number: 20150065516Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: October 29, 2014Publication date: March 5, 2015Inventors: Johannes Aebi, Alfred Binggeli, Cornelia Hertel, Anish Ashok Konkar, Holger Kuehne, Bernd Kuhn, Hans P. Maerki, Halyan Wang
-
Publication number: 20150057458Abstract: Process for the production of a chemical compound from a carbon dioxide starting material, comprising the steps of a) providing a feed stream consisting mainly of carbon dioxide; b) electrolysing in an electrolysis stage the carbon dioxide in the feed stream to a first gas stream containing carbon monoxide and a second gas stream containing oxygen, wherein the molar ratio between carbon monoxide and oxygen is about 1:0.5 in an electrolysis stage; c) adjusting the composition of the first gas stream or the second gas stream or both gas streams to include carbon dioxide, either by operating at less than full conversion of CO2 or by sweeping one or both gas streams with a gas containing CO2 or by at some stage between the electrolysis cell and the oxidative carbonylation reactor diluting one or both gas streams with a gas containing CO2; all while maintaining an overall molar ratio of carbon monoxide to oxygen of about 1:0.Type: ApplicationFiled: April 11, 2013Publication date: February 26, 2015Applicant: Haldor Topsøe A/SInventors: Niels Christian Schjødt, John Bøgild Hansen, Claus Friis Pedersen
-
Patent number: 8962870Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.Type: GrantFiled: November 24, 2010Date of Patent: February 24, 2015Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Patent number: 8962871Abstract: A 4-benzyl-1-methyl-6-oxabicyclo[3,2,0]heptane derivative is manufactured by reducing, in the presence of both a halogenating agent and a hydride-type reducing agent, a methylene moiety bound to a sulfonyloxy group in a compound represented by General Formula (II).Type: GrantFiled: November 5, 2012Date of Patent: February 24, 2015Assignee: Kureha CorporationInventor: Hisashi Kanno
-
Publication number: 20150050713Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: July 25, 2014Publication date: February 19, 2015Inventors: Michael P. Malakhov, Fang Fang
-
Publication number: 20150051269Abstract: The present invention relates to a hydrophobic drug delivery conjugate, to which cyclodextrin, poly(maleic anhydride), and a hydrophobic drug are bonded, and to a pharmaceutical composition comprising the hydrophobic drug delivery conjugate as an active ingredient. The hydrophobic drug delivery conjugate according to the present invention can effectively control the release rate and the delivery rate of a hydrophobic drug by regulating the physicochemical bonding and/or composition of the cyclodextrin, poly(maleic anhydride), and hydrophobic drug, and can also increase the effect of the drug by significantly increasing the solubility of the hydrophobic drug. Further, the present invention can enable the type of the hydrophobic drug to be varied, as well as a peptide having target directivity to be introduced into a surface of the conjugate, such that the present invention can be applied to the treatment of various diseases in addition to cancer treatment.Type: ApplicationFiled: March 12, 2013Publication date: February 19, 2015Inventors: Won Jong Kim, Ran Namgung, Byung Heon Lee, In San Kim, Allan Hoffman
-
Publication number: 20150038564Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.Type: ApplicationFiled: March 7, 2013Publication date: February 5, 2015Inventors: Pavel Vraspir, Alexandr Jegorov, Roman Gabriel, Ales Gavenda
-
Publication number: 20150005517Abstract: Disclosed is a method of crystallizing a taxane comprising combining the taxane and methylene chloride to obtain a solution and adding an anti-solvent to the solution to obtain a crystalline taxane, wherein the anti-solvent is selected from the group consisting of hexane and heptane.Type: ApplicationFiled: February 24, 2014Publication date: January 1, 2015Applicant: Phyton Holdings LLCInventors: James H. Johnson, T.G. Sambandam, Barry J. Hand, Christopher D. Howe, Roland R. Franke, Brian A. Bucher, John S. Juchum, Rex T. Gallagher, Marc A. Plante, Edward M. Desimone, III, Dong S. Yang
-
Publication number: 20150005487Abstract: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, preferably in chromatographic application.Type: ApplicationFiled: September 17, 2012Publication date: January 1, 2015Applicant: INSTRACTION GMBHInventors: Markus Arendt, Björn Degel, Thomas Schwarz, Gerhard Stumm, Martin Welter
-
Patent number: 8921411Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.Type: GrantFiled: July 1, 2013Date of Patent: December 30, 2014Assignee: Plus Chemicals SAInventors: Ondrej Simo, Pavel Vraspir, Tomas Holas, Alexandr Jegorov, Roman Gabriel
-
Publication number: 20140371474Abstract: The invention provides new cabazitaxel isoserine ester intermediates and new synthetic methods, and a preparation method for the anti-tumour drugs cabazitaxel, docetaxel and paclitaxel from the new cabazitaxel isoserine intermediates.Type: ApplicationFiled: October 19, 2012Publication date: December 18, 2014Applicant: Shanghai Bioman Phama LimitedInventors: Yunman Zheng, Tianhui Xu, Ragina Naidu
-
Patent number: 8912229Abstract: The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the abeo-taxanes.Type: GrantFiled: April 6, 2012Date of Patent: December 16, 2014Assignee: Arbor Therapeutics, LLCInventors: James D. McChesney, John T. Henry, Sylesh Venkataraman, Mahesh Kumar Gundluru
-
Patent number: 8912212Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.Type: GrantFiled: September 27, 2013Date of Patent: December 16, 2014Assignee: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Patent number: 8905997Abstract: Disclosed herein are therapeutic compositions for treating and preventing diseases such as neointimal hyperplasia (NIH), where the compositions comprise a therapeutic particle that has a localized association with a blood vessel and a therapeutic agent, such as an anti-NIH agent. Methods of use of the therapeutic compositions are also disclosed.Type: GrantFiled: August 30, 2013Date of Patent: December 9, 2014Assignee: BIND Therapeutics, Inc.Inventors: Amy Grayson, Stephen E. Zale, David Dewitt